It Seems Intercept Pharmaceuticals, Inc. (ICPT) Will Go Up. Have Another Big Increase

February 15, 2018 - By Adrian Mccoy

Investors sentiment decreased to 1.33 in 2017 Q3. Its down 0.26, from 1.59 in 2017Q2. It dropped, as 33 investors sold Intercept Pharmaceuticals, Inc. shares while 30 reduced holdings. 30 funds opened positions while 54 raised stakes. 18.23 million shares or 10.01% less from 20.26 million shares in 2017Q2 were reported.
New York State Common Retirement Fund accumulated 0% or 40,300 shares. Moreover, Rhenman And Prtn Asset Mngmt Ab has 0.3% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 40,000 shares. Birchview Capital Limited Partnership accumulated 4,300 shares. 778 were reported by Tower Research Cap Ltd Liability Corp (Trc). Northern Tru Corp invested in 86,129 shares. 29,200 are held by Swiss Comml Bank. Edge Wealth Mgmt Ltd Liability Corporation holds 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 300 shares. State Board Of Administration Of Florida Retirement accumulated 0% or 26,267 shares. Sg Americas Ltd Company reported 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Federated Investors Pa has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Creative Planning holds 9,820 shares or 0% of its portfolio. 11,307 are held by Citigroup. New York-based Kazazian Asset Limited has invested 0.62% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Invesco holds 0% or 6,280 shares in its portfolio. Millennium Mgmt Ltd Liability Com owns 88,819 shares for 0.01% of their portfolio.

The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is a huge mover today! The stock increased 9.07% or $5.08 during the last trading session, reaching $61.1. About 790,125 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 14.52% since February 15, 2017 and is downtrending. It has underperformed by 31.22% the S&P500.
The move comes after 8 months positive chart setup for the $1.53 billion company. It was reported on Feb, 15 by Barchart.com. We have $64.77 PT which if reached, will make NASDAQ:ICPT worth $92.04 million more.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on February, 22. They expect $-3.39 EPS, up 29.96 % or $1.45 from last year’s $-4.84 per share. After $-2.89 actual EPS reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.30 % negative EPS growth.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 72 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Hold” rating by Needham given on Friday, October 20. The company was downgraded on Friday, April 8 by Morgan Stanley. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Sell” rating given on Wednesday, February 7 by Goldman Sachs. The rating was maintained by Morgan Stanley on Tuesday, May 31 with “Underweight”. The firm has “Neutral” rating given on Thursday, November 2 by Cantor Fitzgerald. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Wednesday, June 1. Wedbush has “Outperform” rating and $239 target. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, April 7. The firm has “Buy” rating given on Tuesday, September 12 by Cowen & Co. Citigroup downgraded the stock to “Neutral” rating in Friday, September 22 report.

More important recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Globenewswire.com which released: “Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial …” on February 14, 2018, also Globenewswire.com published article titled: “Intercept Announces Updated US Prescribing Information for Ocaliva …”, Globenewswire.com published: “Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of …” on February 12, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was released by: Nasdaq.com and their article: “Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva” with publication date: February 15, 2018.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $1.53 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.